Literature DB >> 3257774

Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.

D G Russell1, J Alexander.   

Abstract

The abundant Leishmania promastigote surface Ag gp63 and Leishmania promastigote lipophosphoglycan were reconstituted into liposomes and used as a vaccine against the agent of New World cutaneous leishmaniasis, Leishmania mexicana. The Ag were inoculated s.c., i.p., and i.v. into CBA/ca and BALB/c mice. Even at low Ag dosages, 8 to 10 micrograms/mouse, the Ag induced appreciable levels of protection. In CBA/ca mice complete protection was obtained by s.c. inoculation of antigen-containing liposomes. Protection could be transferred with T cells to naive mice. Interestingly, the Ag-containing liposomes did not cause the disease exacerbation observed in previous vaccine studies with crude parasite extracts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis.

Authors:  K L Lohman; P J Langer; D McMahon-Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  In vitro responses to Leishmania antigens by lymphocytes from patients with leishmaniasis or Chagas' disease.

Authors:  S G Reed; E M Carvalho; C H Sherbert; D P Sampaio; D M Russo; O Bacelar; D L Pihl; J M Scott; A Barral; K H Grabstein
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

4.  Metacyclic neutralizing effect of monoclonal antibody 10D8 directed to the 35- and 50-kilodalton surface glycoconjugates of Trypanosoma cruzi.

Authors:  N Yoshida; R A Mortara; M F Araguth; J C Gonzalez; M Russo
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

5.  The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin.

Authors:  J M Brewer; J Alexander
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

6.  Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic.

Authors:  Fadile Yildiz Zeyrek; Metin Korkmaz; Yusuf Ozbel
Journal:  Clin Vaccine Immunol       Date:  2007-08-29

7.  Novel 17-kilodalton Leishmania antigen revealed by immunochemical studies of a purified glycoprotein fraction recognized by murine T lymphocytes.

Authors:  M M Rodrigues; M T Xavier; L Mendonça-Previato; M A Barcinski
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

8.  Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody.

Authors:  C L Barbiéri; S Giorgio; A J Merjan; E N Figueiredo
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.